News
The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 ...
Weight loss drugs Ozempic and Wegovy would no longer be covered by California’s health insurance for low-income people under ...
Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.
8h
Zacks Investment Research on MSNETFs to Capitalize on the Novo Nordisk-Septerna DealNovo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Explore more
11h
MarketBeat on MSNIs It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results